Influence of standard modifiable risk factors on ventricular tachycardia after myocardial infarction.
LVEF (left ventricular ejection fraction)
electrophysiology study
myocardial infarction
standard modifiable risk factors
ventricular tachycardia
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
08
2023
accepted:
27
09
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Inducible ventricular tachycardia (VT) at electrophysiology study (EPS) predicts sudden cardiac death because of ventricular tachyarrhythmia, the single greatest cause of death within 2 years after myocardial infarction (MI). We aimed to assess the association between standard modifiable risk factors (SMuRFs) and inducible VT at EPS early after MI. Consecutive patients with left ventricle ejection fraction ≤40% on days 3-5 after ST elevation MI (STEMI) who underwent EPS were prospectively recruited. Positive EPS was defined as induced sustained monomorphic VT cycle length ≥200 ms for ≥10 s or shorter if hemodynamically compromised. The primary outcome was inducibility of VT at EPS, and the secondary outcome was all-cause mortality on follow-up. In 410 eligible patients undergoing EPS soon (median of 9 days) after STEMI, 126 had inducible VT. Ex-smokers experienced an increased risk of inducible VT [multivariable logistic regression adjusted odds ratio (OR) 2.0, In patients with recent STEMI and impaired left ventricular function, the presence of any SMuRFs, apart from being a current smoker, conferred an increased risk of inducible VT at EPS. These results highlight the need to modify SMuRFs in this high-risk subset of patients.
Sections du résumé
Background
UNASSIGNED
Inducible ventricular tachycardia (VT) at electrophysiology study (EPS) predicts sudden cardiac death because of ventricular tachyarrhythmia, the single greatest cause of death within 2 years after myocardial infarction (MI).
Objectives
UNASSIGNED
We aimed to assess the association between standard modifiable risk factors (SMuRFs) and inducible VT at EPS early after MI.
Methods
UNASSIGNED
Consecutive patients with left ventricle ejection fraction ≤40% on days 3-5 after ST elevation MI (STEMI) who underwent EPS were prospectively recruited. Positive EPS was defined as induced sustained monomorphic VT cycle length ≥200 ms for ≥10 s or shorter if hemodynamically compromised. The primary outcome was inducibility of VT at EPS, and the secondary outcome was all-cause mortality on follow-up.
Results
UNASSIGNED
In 410 eligible patients undergoing EPS soon (median of 9 days) after STEMI, 126 had inducible VT. Ex-smokers experienced an increased risk of inducible VT [multivariable logistic regression adjusted odds ratio (OR) 2.0,
Conclusions
UNASSIGNED
In patients with recent STEMI and impaired left ventricular function, the presence of any SMuRFs, apart from being a current smoker, conferred an increased risk of inducible VT at EPS. These results highlight the need to modify SMuRFs in this high-risk subset of patients.
Identifiants
pubmed: 37942068
doi: 10.3389/fcvm.2023.1283382
pmc: PMC10628449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1283382Informations de copyright
© 2023 Deshmukh, Kovoor, Byth, Chow, Zaman, Chong, Figtree, Thiagalingam and Kovoor.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Europace. 2014 Jul;16(7):1053-60
pubmed: 24158256
Front Cardiovasc Med. 2022 Apr 14;9:876465
pubmed: 35497977
Heart Rhythm. 2023 Jan;20(1):76-86
pubmed: 36603937
J Am Coll Cardiol. 2003 Jul 2;42(1):81-7
pubmed: 12849664
Pacing Clin Electrophysiol. 2014 Jul;37(7):795-802
pubmed: 24666010
JAMA. 2019 Aug 20;322(7):642-650
pubmed: 31429895
Europace. 2012 Dec;14(12):1771-7
pubmed: 22730377
Cardiovasc Diabetol. 2017 Sep 29;16(1):120
pubmed: 28962617
Europace. 2014 Sep;16(9):1315-21
pubmed: 24599939
Am J Cardiol. 2001 Jan 1;87(1):49-53
pubmed: 11137833
J Am Heart Assoc. 2020 Jul 7;9(13):e015204
pubmed: 32573328
Front Pharmacol. 2021 Jul 08;12:687256
pubmed: 34305599
Circulation. 2014 Feb 25;129(8):848-54
pubmed: 24381209
J Am Coll Cardiol. 1998 Nov;32(5):1454-9
pubmed: 9809962
Circulation. 2009 Jul 21;120(3):194-200
pubmed: 19581496
Europace. 2017 Jun 1;19(6):891-911
pubmed: 28881872
Heart Rhythm. 2011 Apr;8(4):493-9
pubmed: 21129504
Circ Heart Fail. 2015 Jul;8(4):694-701
pubmed: 26038535
Circulation. 1992 May;85(5):1808-15
pubmed: 1572037
Heart Lung Circ. 2020 Jul;29(7):1025-1031
pubmed: 31558356
J Diabetes. 2019 Oct;11(10):794-801
pubmed: 30767398
Lancet. 2021 Mar 20;397(10279):1085-1094
pubmed: 33711294
Am J Cardiol. 2012 Mar 15;109(6):805-12
pubmed: 22196782
Circ Arrhythm Electrophysiol. 2013 Oct;6(5):884-90
pubmed: 23995117
Eur Heart J. 2019 Sep 14;40(35):2940-2949
pubmed: 31049557
Heart Lung Circ. 2016 Nov;25(11):1055-1062
pubmed: 27522511
Circulation. 2014 Jun 10;129(23):2426-35
pubmed: 24914016
J Cardiovasc Electrophysiol. 2010 Mar;21(3):262-9
pubmed: 19817927
Eur Heart J. 2022 Oct 21;43(40):3997-4126
pubmed: 36017572
Heart Rhythm. 2010 Nov;7(11):1589-97
pubmed: 20650333